Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders
Jerold Chun(Sanford Burnham Prebys Medical Discovery Institute), Victoria A. Blaho(Discovery Institute), Yasuyuki Kihara(Sanford Burnham Prebys Medical Discovery Institute), Deepa Jonnalagadda(Sanford Burnham Prebys Medical Discovery Institute)
The Annual Review of Pharmacology and Toxicology
January 6, 2019
Cited by 128
Related Papers
Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain
|Nature Biotechnology|2017|1.1k
Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain
|Science|2016|1.1k
LPA Receptors: Subtypes and Biological Actions
|The Annual Review of Pharmacology and Toxicology|2010|851
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
|Nature Medicine|2007|820
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
|Clinical Neuropharmacology|2010|794